Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.

AIDS. 1998 Aug 20;12(12):1521-7. Unique Identifier : AIDSLINE MED/98394557
Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ; Mahidol University, Phayathai, Bangkok, Thailand.

Abstract: OBJECTIVE: To examine the effect of treatment with an inactivated, gp120-depleted, HIV-1 immunogen (Remune) in 30 Thai subjects infected with HIV-1 subtype E. DESIGN: Sixty-week open-label study. METHODS: Thirty HIV-positive volunteers with CD4 cell counts > or = 300 x 10(6)/l were given intramuscular injections of Remune into the triceps muscle on day 1 and then at weeks 4, 8, 12, 24, 36, 48 and 60. RESULTS: Treatment with Remune was well-tolerated and augmented HIV-1-specific immune responses. Furthermore, subjects had a significant increase in CD4 cell count (P < 0.0001), CD4 cell percentage (P < 0.0001), CD8 cell percentage (P < 0.0001), and body weight (P < 0.0001) compared with pretreatment levels. Fourteen subjects with detectable viral load at day 1 showed a decrease at week 60 (P=0.04). Retrospective Western blot analysis showed 23 subjects with increased intensity of antibody bands and 15 patients showed development of new reactivities to HIV proteins, especially towards p17 and p15. CONCLUSION: These results indicate that HIV-specific immune-based therapeutic approaches such as Remune should be further examined in countries with different clades of HIV-1 and where access to antiviral drug therapies is limited.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adult AIDS Vaccines/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Blotting, Western CD4 Lymphocyte Count Female Human HIV Antibodies/BLOOD HIV Envelope Protein gp120/*IMMUNOLOGY HIV Infections/IMMUNOLOGY/*THERAPY/VIROLOGY HIV-1/*PHYSIOLOGY *Immunotherapy, Active Male RNA, Viral/BLOOD Thailand Time Factors Treatment Outcome Vaccines, Inactivated/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Viral Load
990130
A9911028

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .